Ocuphire Pharma Inc
For the period ended Dec 31, 2023. Filed Mar 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 8, 2024
IRD$4.20+0.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Comprehensive (Loss) Income
(in thousands, except share and per share amounts)
| For the Year Ended December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| License and collaborations revenue | $19,049 | $39,850 |
| Operating expenses: | ||
| General and administrative | 11,959 | 7,269 |
| Research and development | 17,653 | 14,355 |
| Total operating expenses | 29,612 | 21,624 |
| (Loss) income from operations | (10,563) | 18,226 |
| Financing costs (Note 8) | (1,328) | — |
| Interest expense (Note 4) | — | (9) |
| Fair value change in derivative liabilities | 80 | — |
| Other income (expense), net | 1,837 | (14) |
| (Loss) income before income taxes | (9,974) | 18,203 |
| Provision for income taxes | (12) | (315) |
| Net (loss) income | (9,986) | 17,888 |
| Other comprehensive (loss) income, net of tax | — | — |
| Comprehensive (loss) income | $(9,986) | $17,888 |
| Net (loss) income per share (Note 10): | ||
| Basic | $(0.46) | $0.90 |
| Diluted | $(0.46) | $0.87 |
| Number of shares used in per share calculations: | ||
| Basic | 21,589,821 | 19,931,080 |
| Diluted | 21,589,821 | 20,597,212 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.